Removal of BFL-1 sensitises some melanoma cells to killing by BH3 mimetic drugs-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Removal of BFL-1 sensitises some melanoma cells to killing by BH3 mimetic drugs

Published:2022-04-04 Issue:4 Volume:13 Page:
ISSN:2041-4889
Container-title:Cell Death & Disease
language:en
Short-container-title:Cell Death Dis

Author:

Gangoda Lahiru,Schenk Robyn L.,Tai Lin,Szeto Pacman^ORCID,Cheung Jen G.,Strasser Andreas^ORCID,Lessene Guillaume^ORCID,Shackleton Mark^ORCID,Herold Marco J.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Cell Biology,Cellular and Molecular Neuroscience,Immunology

Link

https://www.nature.com/articles/s41419-022-04776-y.pdf

Reference15 articles.

1. Enewold L, Sharon E, Harlan LC. Metastatic melanoma: treatment and survival in the US after the introduction of ipilimumab and vemurafenib. Oncol Res Treat. 2017;40:174–83.

2. Davis EJ, Johnson DB, Sosman JA, Chandra S. Melanoma: what do all the mutations mean? Cancer. 2018;124:3490–9.

3. Eroglu Z, Ribas A. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol. 2016;8:48–56.

4. Johnson DB, Puzanov I. Treatment of NRAS-mutant melanoma. Curr Treat Options Oncol. 2015;16:15.

5. Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311–22.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Last but not least: BFL-1 as an emerging target for anti-cancer therapies;Biochemical Society Transactions;2022-07-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP